Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility ... million), and could create 300 jobs at the plant itself, with another 500 positions required ...

Eli Lilly's links to Purdue University ... The two venerable Indiana institutions - Lilly headquartered in Indianapolis and Purdue in nearby West Lafayette - have been working together for many ...

Eli Lilly has named Winselow Tucker as President and General Manager for India. Tucker will oversee operations, including the Lilly India commercial organization and the Lilly Capability Centre India.

The project will expand Ingredion’s capabilities for delivering texture innovations to growing end markets while bolstering ...

The surveys were conducted before President Donald Trump announced tariffs on imports that risk disrupting supply chains for ...

Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.

Instead, the company announced two years ago it would move its corporate headquarters and build a huge manufacturing plant at a $130 million campus in Noblesville. The 180-acre NorthPoint II ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

I think Eli Lilly and Company's stock correction may ... We'll also bring additional manufacturing capacity online and expect to produce at least 60% more salable doses of incretins in the first ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.